Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
about
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysisPretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-AnalysisPrognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical reviewChemotherapy options in castration-resistant prostate cancerNeutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-AnalysisSafety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.A robust blood gene expression-based prognostic model for castration-resistant prostate cancerBlood-based gene expression profiling in castrate-resistant prostate cancer.The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy.Impact of systemic inflammation on gastric cancer outcomes.Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer.Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer.Preoperative Neutrophil-to-lymphocyte Ratio Predicts Long-term Survival in Patients Undergoing Total Laryngectomy With Advanced Laryngeal Squamous Cell Carcinoma: A Single-center Retrospective Study.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancerPrognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios can Predict Treatment Response to Neoadjuvant Therapy in Esophageal Cancer.Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer.High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer.Prognostic value of the neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.Neutrophils in cancer: prognostic role and therapeutic strategies.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities.Neutrophil-lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer.Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
P2860
Q26773406-130084C2-108E-46DD-B357-1F734C4F02B8Q26786160-5D4D62C3-AC60-4FCF-95D7-920DE54955BFQ28073742-BF934F99-5A7C-4367-BDE3-FAD69338F1B3Q28078477-875F420D-5537-4C77-8E27-FE585F26F598Q28552296-E3CDBE75-FD0B-44EB-B471-0873A85B1113Q33440646-65E2A8CE-5FA0-4A45-B493-C258865F1F27Q33618490-1C7D82CB-B683-4A01-B005-6C5B475BB546Q35752837-BC8DAC57-2FE4-470E-B09B-24EE9525C536Q35772012-DECE06A4-A472-4CC3-8DF2-E6A399EF6FF3Q35845330-1BAF1761-53A1-404A-8B68-D9395A688C1DQ36081801-BC0507EF-94DF-4857-AEB3-AE1161BCA977Q36195647-003FC5AD-E9B7-4D32-B52F-C4067EEC28DAQ36328544-25D06B12-2675-4B73-A6CA-5C087465F130Q36338120-1BC1BD51-6162-4CE7-8E03-EE1BA694A12FQ36524772-F7E2E8F4-58B4-4B40-9A34-F73B5C6BA485Q36580936-E77256E5-B84E-4EBF-8218-EAC5C3ECA285Q37335554-0F000043-A0E0-469F-A7BA-50EA09947040Q37479765-7B7E9C53-D9C0-4FE3-A2E8-792B06818F91Q38623275-2CA9DAEA-6098-4BD2-8C8D-B0EE38499F1CQ38655670-1A802FEF-C7BD-46FE-A60A-7D2E05414A6BQ38978620-2348EB31-FE74-4315-BE74-6875B8D6A43DQ38994718-52486A9F-D37C-4519-A09C-996397177840Q39031750-6BF9C083-74AB-4C16-82A0-1E2D5B35EC9FQ39085035-5ECF9D2D-83FF-4D4B-9A4F-38E750BC866DQ39479184-715893A2-9729-413D-BFB5-A98991830285Q39641273-7AC6C95A-BE03-4E0D-969F-7DF7CFB0489CQ39651226-8CE51ACC-7C3E-482F-AA9E-25BED07BE0D1Q40121315-56705830-838D-441C-B10F-587FFFDDEADFQ40169794-17CD8D00-7292-43A0-95EE-5014F099FDA9Q40332155-93EE17D0-72DB-45AD-8A25-7A8245954EEEQ40510647-B6A171EE-FCD9-4B8D-8282-D9133D5E36A8Q40572565-B44F8694-FA03-4A2F-B9DA-5EFEBE95EA93Q41431390-0B78D5F3-B174-4B18-8BE7-20D151702388Q41777743-2040E944-8A39-4A03-9375-6EA3B03997ABQ41867950-CE1B056B-17B0-4031-8CA8-4751C7B91DB7Q42378704-7E493507-A1D8-4292-8D66-1C051E70A286Q43144351-BA61C1E8-8975-4880-ACF7-A750C7053C70Q47152345-773944E2-A19C-4D8A-822C-C7056F1741FCQ47449416-E81DB8A0-A2E5-4A4A-A9C9-B864527171ACQ48110667-3336E1EE-58AA-47D9-A232-89868816DD1B
P2860
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Baseline neutrophil-lymphocyte ...... ndent of baseline steroid use.
@en
Baseline neutrophil-lymphocyte ratio
@nl
type
label
Baseline neutrophil-lymphocyte ...... ndent of baseline steroid use.
@en
Baseline neutrophil-lymphocyte ratio
@nl
prefLabel
Baseline neutrophil-lymphocyte ...... ndent of baseline steroid use.
@en
Baseline neutrophil-lymphocyte ratio
@nl
P2093
P2860
P356
P1433
P1476
Baseline neutrophil-lymphocyte ...... ndent of baseline steroid use.
@en
P2093
A J Templeton
D Bianchini
J S de Bono
R Ferraldeschi
Z Zafeiriou
P2860
P304
P356
10.1093/ANNONC/MDU587
P577
2014-12-23T00:00:00Z